Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 911

1.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
2.

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group.

J Clin Psychiatry. 2005 Feb;66(2):238-47.

PMID:
15705011
3.

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.

Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G; SAD 388 Study Group.

Hum Psychopharmacol. 2004 Aug;19(6):387-96.

PMID:
15303242
4.
5.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
6.

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.

Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A.

Arch Gen Psychiatry. 2004 Nov;61(11):1153-62.

PMID:
15520363
7.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
8.

Controlled-release paroxetine in the treatment of patients with social anxiety disorder.

Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L.

J Clin Psychiatry. 2004 Feb;65(2):222-9.

PMID:
15003077
9.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
10.

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD.

J Clin Psychiatry. 2002 Jan;63(1):66-74.

PMID:
11838629
11.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
12.
13.

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.

Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.

Depress Anxiety. 2007;24(1):1-14.

PMID:
16894619
14.

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.

Stein DJ, Versiani M, Hair T, Kumar R.

Arch Gen Psychiatry. 2002 Dec;59(12):1111-8.

PMID:
12470127
15.
16.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
17.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817
19.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
20.

Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.

Sheehan DV, Burnham DB, Iyengar MK, Perera P; Paxil CR Panic Disorder Study Group.

J Clin Psychiatry. 2005 Jan;66(1):34-40.

PMID:
15669886

Supplemental Content

Support Center